- TLDR Biotech
- Archive
- Page 3
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | September 24 - 25, 2025
🧬 FDA draft docs for faster CGT drug development, Eli Lilly lands a pair of approvals (FDA approval for oral SERD in breast cancer + EC approval for Kisunla in early symptomatic Alzheimer's), Merck & Co. in-licenses Evaxion's AI-platform based vaccine candidate for $7.5M upfront + $592M biobucks, NIH pledges $87M for organoid center in accelerating shift away from animal testing, UK may attempt big pharma damage control by "fix[ing] the commercial environment" (raising prescription drug prices)
Biotech & Pharma Updates | September 23 - 24, 2025
🧬 uniQure's Huntington's gene therapy slows down disease progression by 75% over 3 years in Ph2 trial, Glenmark signs up to $1B ADC deal with Hengrui Pharma, Roche presents new Ocrevus data with "significant benefit" in preventing MS-related disability progress, Moderna opens new UK vaccine manufacturing/R&D site amongst other big pharma exits, Fujifilm Biotechnologies opens doors to new $3.2B facility as one of the "largest cell culture biomanufacturing sites in the U.S.", Sparrow Pharmaceuticals lands $95M Series B to help T2D patients with elevated cortisol
Biotech & Pharma Updates | September 22 - 23, 2025
🧬 Eli Lilly drops $6.5B on Houston API plant, BMS' multiple myeloma protein degrader iberdomide hits a Ph3 goal, Merck & Co. commits further $349M into Variational AI drug discovery partnership, atai Life Sciences & Beckley Psytech report positive Ph2a data for DMT analog in treatment resistant depression, Sanofi commits further $625M into venture investment arm Sanofi Ventures, Manas AI touts $26M seed extension for "full-stack, AI native drug discovery and development"
Biotech & Pharma Updates | September 21 - 22, 2025
🧬 Pfizer's $4.9B obesity play with Metsera acquisition, Avenzo Tx's $60M Series B for "best-in-class oncology drug", Until's organ cryopreservation ambitions lead to $58M Series A, Roche posts Ph3 win for oral selective estrogen receptor degrader in breast cancer, Ionis' Alexander disease antisense oligonucleotide Phase 3 win, Trump admin continues baffling everyone - now linking Tylenol use in pregnancy to autism
Biotech & Pharma Updates | September 18 - 21, 2025
🧬 Merck & Co.'s Keytruda gets subcutaneous FDA ok, Novo Nordisk's once-weekly Type 2 diabetes combo-therapy lands CHMP nod, Merck KGaA opens €150m "climate-neutral" Cork Ireland facility, Eli Lilly plans orforglipron launch in India (citing no cold chain required versus weight-loss injectables), AusperBio lands $63M Series B2 towards chronic hep B functional cures, "bombardment of [Facebook] spam" lands Eli Lilly in UK marketing watchdog hot water
Biotech & Pharma Updates | September 17 - 18, 2025
🧬 Roche dives into MASH space with $2.4B 89bio buy, T.Rx Capital launches with $77.5M to bet on companies at the "intersection of technology & biology", MilliporeSigma opens €150M (+200 jobs) filtration plant in Ireland, Lexicon pushes non-opioid pain hopeful pilavapadin to Ph3 after post-hoc analysis, Fujifilm + argenx partner on US-based Vyvgart manufacturing, Carisma looks all but sunk as reverse-merger slips and BioNTech leaves partnership, bluebird bio rebrands as (old name) Genetix Biotherapeutics
Biotech & Pharma Updates | September 16 - 17, 2025
🧬 Ollin's $100M eye disease drug launch (going after Roche and Amgen), Biogen lands EC approval for Zurzuvae (zuranolone) in postpartum depression, Novo Nordisk and Eli Lilly both announce Ph3 oral GLP-1 data, J&J aims to snatch BMS' psoriasis crown with new icotrokinra data, ARTHEx Biotech Series B upsized to $87M (going after Myotonic Dystrophy Type 1), ArsenalBio cuts 50% of staff despite $325M raise last year, Novo Nordisk + BMS announce 250+ layoffs a piece in New Jersey
Biotech & Pharma Updates | September 15 - 16, 2025
🧬 GSK's $30B US manufacturing investment commitment, Novo & Eli Lilly announce separate Ph3 obesity trail data (injectable & oral respectively), Dualitas launches w/$65M to build a "novel bispecific discovery engine", AstraZeneca's Imfinzi lands NHS nod for limited-stage NSCLC, CSL buys options to internal bleeding-prevention med VMX-C001 from VarmX ($117M upfront + $2B biobucks), Reunion Neuroscience updates Series A to $133M for "psychedelic-inspired therapeutic solutions", AGC plots Colorado plant sale + 278 layoffs
Biotech & Pharma Updates | September 14 - 15, 2025
🧬 Novartis + Monte Rosa's protein degrader deal ($120M upfront + $5.7B biobucks), Lila Sciences secures $235M Series A to automate the drug discovery process, BMS sell majority stake in historic US-China pharma joint venture, Novo Nordisk's GLP-1 Rybelsus nabs EU label extension into cardiovascular benefits, CBER Director back-tracks on earlier ad-comm "scrapping" comments, Revvity shutters Mass. facility (74 jobs cut), ATyr shares plummet after ATYR1923's pulmonary sarcoidosis Ph3 flop
Biotech & Pharma Updates | September 11 - 14, 2025
🧬 Lila Sciences' "autonomous science" ambitions could net it a $300M+ fundraise, Medicines Discovery Catapult + Crown Bioscience partner on radiopharma development, UK's biopharma industry dealt multiple blows as both AstraZeneca & Eli Lilly reconsider initiatives there, vaccine stocks slide over rumors of Trump admin linking COVID shots to 25 children deaths
